Aktienanalyse zu NU Skin Enterprises Inc (NUS)NUSNU Skin Enterprises Inc

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.